methylphenylcarbinyl acetate: structure
ID Source | ID |
---|---|
PubMed CID | 62341 |
CHEMBL ID | 3184429 |
CHEBI ID | 180412 |
SCHEMBL ID | 114793 |
MeSH ID | M0055588 |
Synonym |
---|
CHEBI:180412 |
nsc2397 |
gardeniol ii |
gardenol |
.alpha.-methylbenzyl acetate |
.alpha.-phenylethyl acetate |
styralyl acetate |
phenylmethylcarbinyl acetate |
1-phenylethyl acetate |
93-92-5 |
sec-phenylethyl acetate |
methylphenylcarbinol acetate |
nsc-2397 |
methylphenylcarbinyl acetate |
.+/-.-.alpha.-methylbenzyl acetate |
benzyl alcohol, .alpha.-methyl-, acetate |
benzenemethanol, .alpha.-methyl-, acetate |
styrylallyl acetate |
ai3-18152 |
alpha-methylbenzenemethanol acetate |
benzyl alcohol, alpha-methyl-, acetate |
benzenemethanol, alpha-methyl-, acetate |
alpha-methylbenzyl alcohol acetate |
fema no. 2684 |
alpha-methylbenzyl acetate |
styrallyl acetate |
brn 1908635 |
einecs 202-288-5 |
nsc 2397 |
alpha-phenylethyl acetate |
sec-phenethyl acetate |
methyl phenyl carbinyl acetate |
methyl phenylcarbinyl acetate, >=98%, fcc, fg |
29759-11-3 |
methylbenzyl acetate |
NCGC00248223-01 |
NCGC00254850-01 |
dtxsid6041636 , |
cas-93-92-5 |
tox21_300948 |
(+/-)-alpha-methylbenzyl acetate |
dtxcid4021636 |
acetic acid 1-phenyl-ethyl ester |
unii-p4rvp859f5 |
benzenemethanol, methyl-, acetate |
p4rvp859f5 , |
benzyl alcohol, methyl-, acetate |
AKOS015964844 |
fys3e9nba3 , |
benzenemethanol, alpha-methyl-, 1-acetate |
ec 202-288-5 |
unii-fys3e9nba3 |
4-06-00-03037 (beilstein handbook reference) |
FT-0628865 |
SCHEMBL114793 |
.alpha.-methylbenzyl acetate [fhfi] |
methyl phenylcarbinyl acetate [fcc] |
methyl phenylcarbinyl acetate |
racemic 1-phenylethyl acetate |
1-acetoxy-1-phenylethane |
.alpha.-methylbenzyl alcohol, acetate |
W-100224 |
CHEMBL3184429 |
alpha-methylbenzyl acetate, analytical standard |
mfcd00008858 |
fema 2684 |
styralyl acetate;alpha-methylbenzyl acetate; methyl phenylcarbinyl acetate |
DS-6630 |
E75947 |
AMY4146 |
Q27278293 |
A859619 |
alpha-methylbenzyl acetate; methyl phenylcarbinyl acetate |
benzenemethanol, a-methyl-, acetate |
CS-0154089 |
Class | Description |
---|---|
carboxylic ester | An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 61.6448 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (50.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 3 (50.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |